Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 11/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.38 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.38 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594660 | 0.85 | ALDH1A1 (0.38) | ALDH1A1GPR119LMNAMAPK1MAPT | |
| SCHEMBL12467313 | 0.84 | GPR119 (0.39) | ALDH1A1GPR119LMNAMAPK1POLB | |
| SCHEMBL31501258 | 0.82 | KCNH2 (0.38) | ALDH1A1GPR119LMNAMAPK1 | |
| SCHEMBL22941220 | 0.81 | GPR119 (0.40) | FFAR4ALDH1A1GPR119LMNAMAPK1 | |
| SCHEMBL966486 | 0.78 | GPR119 (0.39) | ALDH1A1GPR119LMNAMAPK1POLB | |
| SCHEMBL3018349 | 0.78 | GPR119 (0.44) | ALDH1A1GPR119LMNAMAPK1POLB | |
| SCHEMBL3306431 | 0.77 | FFAR4 (0.37) | FFAR4FFAR1SLC6A1GABRA5GABRB2 | |
| SCHEMBL13327501 | 0.77 | FFAR4 (0.37) | FFAR4FFAR1SLC6A1GABRA5GABRB2 | |
| SCHEMBL25204166 | 0.76 | CYP2D6 (0.46) | ALDH1A1GPR119LMNAMAPK1POLB | |
| SCHEMBL966487 | 0.75 | FFAR4 (0.36) | FFAR4FFAR1SLC6A1GABRA5GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038268-A2 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-03-25 | — | — | EP | claimed |
| WO-2007148208-A2 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-27 | — | — | WO | claimed |
| EP-1870405-A1 | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2007-12-26 | — | — | EP | claimed |
| CN-118076581-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20210070708-A1 | Pharmaceutically Active Compounds | BERGENBIO ASA (NO) | 2021-03-11 | — | — | US | disclosed |
| US-10766861-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2020-09-08 | — | — | US | disclosed |
| WO-2019196780-A1 | NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 信达生物制药(苏州)有限公司 | 2019-10-17 | — | — | WO | disclosed |
| US-10336702-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2019-07-02 | — | — | US | disclosed |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | BERGENBIO AS (NO) | 2018-02-01 | — | — | US | disclosed |
| EP-3240784-A2 | INHIBITORS OF AKT KINASE | BerGenBio ASA (NO) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016102672-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS | BERGENBIO AS (NO) | 2016-06-30 | — | — | WO | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| WO-2003062265-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20010009912-A1 | NEW DERIVATIVES OF PYRIDIL PIPERAZINE OR PYRIDAZINYL PIPERAZYL, PROCESS FOR PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THESE COMPOUNDS | TSAKLAKIDIS CHRISTOS (DE) | 2001-07-26 | — | — | US | disclosed |
| US-5977110-A | Substituted cyclohexylamines as central nervous systems agents | WARNER-LAMBERT COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1997011070-A1 | SUBSTITUTED CYCLOHEXYLAMINES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-03-27 | — | — | WO | disclosed |
| WO-1992012977-A1 | SUBSTITUTED INDOLES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1992-08-06 | — | — | WO | disclosed |
| US-5124332-A | Dopaminergic agents, hypotensive agents | WARNER-LAMBERT COMPANY (US) | 1992-06-23 | — | — | US | disclosed |
| US-4988699-A | Treatment of psychological disorders such as schizophrenia, as antipsychotic agents and hypotensive agents | WARNER-LAMBERT COMPANY (US) | 1991-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336702-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | FFAR4 3710/4885FFAR1 3634/4885SLC6A1 1605/4885 |
| US-20010009912-A1 | NEW DERIVATIVES OF PYRIDIL PIPERAZINE OR PYRIDAZINYL PIPERAZYL, PROCESS FOR PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THESE COMPOUNDS | CYP4B1, NR4A1, CYP3A43 | FFAR4 1872/4885FFAR1 2884/4885SLC6A1 4575/4885 |
| US-20210070708-A1 | Pharmaceutically Active Compounds | UGT2B7, CYP3A5, UGT1A1 | FFAR4 3679/4885FFAR1 3568/4885SLC6A1 1666/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | FFAR4 4655/4885FFAR1 4563/4885SLC6A1 4726/4885 |
| US-10766861-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | FFAR4 3679/4885FFAR1 3568/4885SLC6A1 1666/4885 |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | UGT2B7, CYP3A5, UGT1A1 | FFAR4 3710/4885FFAR1 3634/4885SLC6A1 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.